Zobrazeno 1 - 10
of 58
pro vyhledávání: '"Xueyan Liang"'
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-10 (2024)
Abstract The RATIONALE-306 study revealed that patients with advanced or metastatic oesophageal squamous cell carcinoma (OSCC) could benefit from treatment with tislelizumab plus chemotherapy. This study aimed to evaluate the cost-effectiveness of ti
Externí odkaz:
https://doaj.org/article/1a62db1528ad4e96a3f850aa3aff4b0c
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-10 (2024)
Abstract Patients with PD-L1-positive esophageal squamous-cell carcinoma (ESCC) were significantly more likely to survive when treated with serplulimab plus cisplatin plus 5-fluorouracil (serplulimab-CF). At this point, it is unknown whether this exp
Externí odkaz:
https://doaj.org/article/20e9bb9f595240ad9cf17fdeee42dcc5
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-9 (2024)
Abstract In the CheckMate 651 study, nivolumab plus ipilimumab versus EXTREME (cisplatin/carboplatin + cetuximab + fluorouracil) regimen was compared for effectiveness. It is not known whether these immunotherapy agents are cost-effective for recurre
Externí odkaz:
https://doaj.org/article/b9a4c3bf36034450a2b9ccf15beb9eb7
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
ObjectivesImmune checkpoint inhibitors (ICIs) have revolutionized the treatment of non-small cell lung cancer (NSCLC). However, the application of ICIs can also cause treatment-related adverse events (trAEs) and immune-related adverse events (irAEs).
Externí odkaz:
https://doaj.org/article/4f0f9cf5b4ba451986330b37a7b1225d
Publikováno v:
Chinese Medical Journal, Vol 136, Iss 18, Pp 2156-2165 (2023)
Abstract. Background:. Immune checkpoint inhibitors (ICIs) are standard treatments for advanced non-small cell lung cancer (NSCLC); however, evidence regarding their relative efficacy and safety is lacking. This study compared the efficacy and safety
Externí odkaz:
https://doaj.org/article/daa9d428fa154d4eafa3b079712ab4bc
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 1 (2024)
Background Among patients with advanced/metastatic triple-negative breast cancer (TNBC) with high/positive programmed death-ligand 1 (PD-L1) expression, a superior survival outcome has been demonstrated with immune checkpoint inhibitors (ICIs). Howev
Externí odkaz:
https://doaj.org/article/1984fa1fc5144385a00df8e7b9fff320
Publikováno v:
Frontiers in Public Health, Vol 11 (2023)
BackgroundFor patients with extensive-stage small cell lung cancer (ES-SCLC), serplulimab plus chemotherapy is beneficial as the first-line treatment. It is uncertain whether serplulimab plus chemotherapy will be more cost-effective. The aim of this
Externí odkaz:
https://doaj.org/article/2d1af7a7f0374753b4eedffa9b706abc
Publikováno v:
Frontiers in Endocrinology, Vol 14 (2023)
BackgroundThe optimal first-line immune checkpoint inhibitor (ICI) treatment strategy for metastatic or early triple-negative breast cancer (TNBC) has not yet been determined as a result of various randomized controlled trials (RCTs). The purpose of
Externí odkaz:
https://doaj.org/article/66ddd0227a4640c3bf4d3f7df008ec0c
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
BackgroundThe efficiency and safety of sacituzumab govitecan (SG) for the therapy of hormone receptor-positive (HR+)/human epidermal receptor 2-negative (HER2-) metastatic breast cancer (BC) has been demonstrated. The aim of this study is to evaluate
Externí odkaz:
https://doaj.org/article/632d5c887efa4f399fe1f791726381e5
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
BackgroundIn patients with advanced non-small cell lung cancer (aNSCLC), cemiplimab plus chemotherapy prolonged overall survival (OS) and progression-free survival (PFS) significantly compared to chemotherapy alone. The cost-effectiveness of these dr
Externí odkaz:
https://doaj.org/article/63d7db19e5894029adc9b06141ed83a6